Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.